Literature DB >> 30590835

A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma.

Howard Colman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30590835      PMCID： PMC6303428          DOI： 10.1093/neuonc/noy190

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

Review 1.  Adaptive clinical trials in oncology.

Authors:  Donald A Berry
Journal:  Nat Rev Clin Oncol       Date:  2011-11-08       Impact factor: 66.675

2.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.

Authors:  Janet Woodcock; Lisa M LaVange
Journal:  N Engl J Med       Date:  2017-07-06       Impact factor: 91.245

3.  The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Authors:  Alyssa M Vanderbeek; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Tianqi Chen; Robert Redd; Giovanni Parmigiani; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

4.  Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.

Authors:  Elke Pfaff; Tobias Kessler; Gnana Prakash Balasubramanian; Anne Berberich; Daniel Schrimpf; Antje Wick; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; David Capper; Irini Schenkel; Andreas Eisenmenger; Susan Dettmer; Benedikt Brors; Michael Platten; Stefan M Pfister; Andreas von Deimling; David T W Jones; Wolfgang Wick; Felix Sahm
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

Review 5.  Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Authors:  Brian M Alexander; Sujuan Ba; Mitchel S Berger; Donald A Berry; Webster K Cavenee; Susan M Chang; Timothy F Cloughesy; Tao Jiang; Mustafa Khasraw; Wenbin Li; Robert Mittman; George H Poste; Patrick Y Wen; W K Alfred Yung; Anna D Barker
Journal:  Clin Cancer Res       Date:  2017-08-16       Impact factor: 12.531

6.  N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

Authors:  Wolfgang Wick; Susan Dettmer; Anne Berberich; Tobias Kessler; Irini Karapanagiotou-Schenkel; Antje Wick; Frank Winkler; Elke Pfaff; Benedikt Brors; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; Andreas Eisenmenger; Andreas von Deimling; David T W Jones; Stefan M Pfister; Felix Sahm; Michael Platten
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

Review 7.  MGMT testing--the challenges for biomarker-based glioma treatment.

Authors:  Wolfgang Wick; Michael Weller; Martin van den Bent; Marc Sanson; Markus Weiler; Andreas von Deimling; Christoph Plass; Monika Hegi; Michael Platten; Guido Reifenberger
Journal:  Nat Rev Neurol       Date:  2014-06-10       Impact factor: 42.937

8.  Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Authors:  Shyam K Tanguturi; Lorenzo Trippa; Shakti H Ramkissoon; Kristine Pelton; David Knoff; David Sandak; Neal I Lindeman; Azra H Ligon; Rameen Beroukhim; Giovanni Parmigiani; Patrick Y Wen; Keith L Ligon; Brian M Alexander
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

9.  Toward more informative biomarker-based clinical trials in glioblastoma.

Authors:  Howard Colman
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.